NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing non-antibiotic anti-infective products focused on the global eye care market, today announced that the Company’s Chief Financial Officer, Thomas Paulson will present at the 27th Annual ROTH Capital Partners Conference on Wednesday, March 11, 2015, at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time). The conference is being held at the Ritz-Carlton Laguna Niguel in Dana Point, Calif.
To arrange a meeting with management, please contact firstname.lastname@example.org at: 310-691-7100.
A live webcast and replay will be available on the Investors section of the Company’s website at http://novabay.com/investors/events.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is focused on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX™ Family of Products, including AVENOVA™ for the eye care market and NEUTROPHASE® for wound care, which was initially cleared by FDA, and CELLERX™ for the dermatology market; and its AGANOCIDE® compounds, led by AURICLOSENE™.
NovaBay is partnered in the U.S. and around the globe with: PBE, Inc. (USA), IHT, Inc. (USA), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (Korea), and Biopharm (North African and Middle East).
Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website
At the Company:
Thomas J. Paulson
Chief Financial Officer
Contact T. Paulson